De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade

PHASE2TerminatedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

January 17, 2022

Primary Completion Date

November 26, 2024

Study Completion Date

November 26, 2024

Conditions
HER2-positive Breast CancerER-Negative Breast CancerPR-Negative Breast CancerNode-negative Breast Cancer
Interventions
DRUG

Pertuzumab and tratuzumab fixed dose combination

Treatment administration: adjuvant pertuzumab and trastuzumab fixed dose combination SC for 14 cycles

DRUG

Trastuzumab emtansine

Treatment administration: adjuvant T-DM1 for 14 cycles.

Trial Locations (85)

Unknown

Icon Cancer Centre Wesley, Auchenflower

Ballarat Health Services, Ballarat

Bendigo Hospital, Bendigo

Sunshine Coast University Hospital, Birtinya

Box Hill Hospital, Box Hill

Chris O'Brien Lifehouse, Camperdown

Monash Medical Centre (Clayton), Clayton

Coffs Harbour Health Campus, Coffs Harbour

Concord Repatriation General Hospital, Concord

Townsville University Hospital, Douglas

Lake Macquarie Private Hospital, Gateshead

Gosford Hospital, Gosford

Royal Brisbane and Women's Hospital, Herston

Icon Cancer Centre Hobart, Hobart

Liverpool Hospital, Liverpool

Peter MacCallum Cancer Centre, Melbourne

Sir Charles Gairdner Hospital, Nedlands

Macquarie University, North Ryde

Mater Hospital, North Sydney

Sunshine Hospital, Saint Albans

Calvary Mater Newcastle, Waratah

Westmead Hospital, Westmead

Princess Alexandra Hospital, Woolloongabba

GZA Ziekenhuisen Campus Sint-Augustinus - Iridium Kankernetwerk, Antwerp

OLV ziekenhuis, Aalst

Cliniques Universtaires Saint-Luc, Brussels

Institut Jules Bordet, Brussels

Grand Hôpital de Charleroi, Charleroi

Heilig Hartziekenhuis, Lier

Centre Hospitalier Chretien MontLegia, Liège

CHU UCL Namur Sainte-Elisabeth, Namur

Institut de Cancérologie de l'Ouest - Angers, Angers

Institut Sainte Catherine, Avignon

Centre Hospitalier de la Côte Basque, Bayonne

CHRU Jean Minjoz, Besançon

Institut Bergonié, Bordeaux

Polyclinique Bordeaux Nord Aquitaine, Bordeaux

CHU Morvan, Brest

Centre François Baclesse, Caen

Centre Jean Perrin, Clermont-Ferrand

Centre Georges François Leclerc, Dijon

Hopital Michallon, Grenoble

Centre Oscar Lambret, Lille

CHU de Limoges, Limoges

GHBS Lorient, Lorient

Centre Léon Bérard, Lyon

Institut Paoli Calmettes, Marseille

CH Annecy Genevois, Metz-Tessy

Centre de Cancerologie du Grand Montpellier, Montpellier

Hopital privé du Confluent, Nantes

Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris

Hopital Tenon, Paris

Institut Curie - Paris, Paris

CH Perpignan, Perpignan

Hopital Lyon Sud, Pierre-Bénite

CHU Poitiers, Poitiers

Institut Godinot, Reims

Centre Henri Becquerel, Rouen

Institut Curie - Saint-Cloud, Saint-Cloud

Clinique Saint Anne, Strasbourg

Institut Claudius Regaud, Toulouse

Institut Gustave Roussy, Villejuif

Sheba Medical Center, Ramat Gan

Soon Chun Hyang University Cheonan Hospital, Cheonan

Keimyung University Dongsan Hospital, Daegu

National Cancer Center, Goyang-si

Gachon University Gil Medical Center, Incheon

Inha University Hospital, Incheon

Seoul National University Bundang Hospital, Seongnam

CHA bundang Medical Center, Seongnam-si

Asan Medical Center, Seoul

Ewha Womans University Mokdong Hospital, Seoul

Korea university anam hospital, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Seoul ST. Mary's Hospital, Seoul

Severance Hospital, Seoul

Ajou University Hospital, Suwon

Ulsan University Hospital, Ulsan

Hirslanden Klinik - Tumor Zentrum, Aarau

Kantonsspital Baden, Baden

Universitatsspital Basel, Basel

Kantonsspital Frauenfeld/Frauenklinik, Frauenfeld

Hopital Daler - Centre du Sein, Fribourg

Kantonsspital Winterthur, Winterthur

All Listed Sponsors
collaborator

Breast International Group

OTHER

collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

International Drug Development Institute

OTHER

collaborator

Institut Curie

OTHER

lead

Jules Bordet Institute

OTHER